NorthWest Biotherapeutics Inc (NWBO)

[antihama]

The PIM designation for DCVax-L covers all malignant gliomas, which would include both Glioblastoma multiforme (the most severe grade) as well as less malignant grades, and would include both newly diagnosed and recurrent gliomas.

The PIMS designation under EAMS (“Early Access to Medicines Scheme”) ship has sailed but you know what they say "where's there's smoke there's fire". https://www.sec.gov/Archives/edgar/data/1072379/000114420414056638/v389406_ex99-1.htm